Search | Clinical Trials Finder

Conditions: Glaucoma
Interventions: Gen 2 Travoprost Intracameral Implant, Timolol eye drops 0.5%, Sham Procedure, placebo eye drops; Drug · Procedure · Other
Lead sponsor: Glaukos Corporation; Industry
Eligibility: 18 Years and older
Enrollment: 510 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2032
U.S. locations: 1
States / cities: Dothan, Alabama

Conditions: Glaucoma, Ocular Hypertension
Interventions: fixed combination of brimonidine tartrate 0.2% timolol maleate 0.5% ophthalmic solution, latanoprost 0.005%; Drug
Lead sponsor: Allergan; Industry
Eligibility: 18 Years and older
Enrollment: 148 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2010
U.S. locations: 1
States / cities: Slingerlands, New York

Conditions: Open Angle Glaucoma, Ocular Hypertension
Interventions: Travoprost Ophthalmic Topical Cream low-dose, Travoprost Ophthalmic Topical Cream mid-dose, Travoprost Ophthalmic Topical Cream high-dose, Timolol maleate ophthalmic solution, 0.5%, Travoprost Ophthalmic Solution, 0.004%; Drug
Lead sponsor: Glaukos Corporation; Industry
Eligibility: 18 Years and older
Enrollment: 250 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: Newport Beach, California

Conditions: Ocular Hypertension, Glaucoma
Interventions: AR-13324 Ophthalmic Solution 0.02%, AR-13324 Ophthalmic Solution 0.02% BID, Timolol maleate Ophthalmic Solution 0.5% BID, Placebo; Drug · Other
Lead sponsor: Aerie Pharmaceuticals; Industry
Eligibility: 19 Years to 99 Years
Enrollment: 93 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 1
States / cities: Bedminster, New Jersey

Conditions: Glaucoma, OHT - Ocular Hypertension
Interventions: Timolol 0.5% ophthalmic solution, Latanoprost 0.005% Ophthalmic Solution; Drug
Lead sponsor: Ohio State University; Other
Eligibility: 30 Years and older
Enrollment: 59 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2025
U.S. locations: 3
States / cities: Rochester, Minnesota • Omaha, Nebraska • Columbus, Ohio

Conditions: Glaucoma, Ocular Hypertension
Interventions: OTX-TP, Timolol; Drug
Lead sponsor: Ocular Therapeutix, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 72 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 1
States / cities: Fayetteville, Arkansas

Conditions: Cataract, Glaucoma, Ocular Hypertension
Interventions: Bimatoprost Implant System, SpyGlass IOL, Timolol Maleate Ophthalmic Solution, 0.5%, Commercial IOL; Drug · Device
Lead sponsor: SpyGlass Pharma, Inc.; Industry
Eligibility: 22 Years and older
Enrollment: 400 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2031
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Open-angle Glaucoma, Ocular Hypertension
Interventions: AL-37807 Ophthalmic Suspension, 1.0%, Latanoprost, 0.005% (Xalatan), AL-37807 Vehicle, Timolol Maleate Ophthalmic Gel Forming Solution, 0.5%; Drug · Other
Lead sponsor: Alcon Research; Industry
Eligibility: 18 Years and older
Enrollment: 87 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2006
U.S. locations: 1
States / cities: Fort Worth, Texas

Conditions: Primary Open-Angle Glaucoma (POAG), Ocular Hypertension (OHT)
Interventions: Trabodenoson, Latanoprost, Timolol; Drug
Lead sponsor: Inotek Pharmaceuticals Corporation; Industry
Eligibility: 18 Years and older
Enrollment: 101 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 1
States / cities: Bristol, Tennessee

Conditions: Open Angle Glaucoma
Interventions: Simbrinza 0.2%-1% Ophthalmic Suspension, Rocklatan 0.02%-0.005% Ophthalmic Solution, Cosopt PF 2%-0.5% Ophthalmic Solution, Latanoprost 0.005% Ophthalmic Solution; Drug
Lead sponsor: Prairie Eye Center; Other
Eligibility: 18 Years and older
Enrollment: 70 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Springfield, Illinois

Conditions: Open Angle Glaucoma (OAG), Glaucoma
Interventions: Netarsudil 0.02% Ophthalmic Solution [RHOPRESSA], Timolol Maleate 0.25% Ophthalmic Solution; Drug
Lead sponsor: Brett King; Other
Eligibility: 18 Years and older
Enrollment: 13 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Bloomington, Indiana

Conditions: Glaucoma, Ocular Hypertension
Interventions: 0.2% brimonidine/0.5% timolol fixed combination ophthalmic solution, Concurrent brimonidine 0.2% and Timolol 0.5% ophthalmic solution, Brimonidine 0.2% ophthalmic solution; Drug
Lead sponsor: Allergan; Industry
Eligibility: 18 Years and older
Enrollment: 432 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2004
U.S. locations: 1
States / cities: El Paso, Texas

Conditions: Thyroid Eye Disease, Ocular Hypertension, Glaucoma
Interventions: Prostaglandin Analog, Timolol; Drug
Lead sponsor: Stanford University; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 1
States / cities: Stanford, California

Conditions: Glaucoma, Ocular Hypertension
Interventions: fixed combination of brimonidine tartrate 0.2% timolol maleate 0.5% ophthalmic solution; bimatoprost 0.03% ophthalmic solution, bimatoprost 0.03% ophthalmic solution; hypromellose 0.2% eyedrops; Drug
Lead sponsor: Allergan; Industry
Eligibility: 18 Years and older
Enrollment: 121 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Glaucoma, Open-Angle, Ocular Hypertension
Interventions: AGN-207281 ophthalmic solutions (0.1% and 0.3%); AGN-207281 vehicle ophthalmic solution (placebo), timolol ophthalmic solution 0.5%, AGN-207281 vehicle ophthalmic solution (Placebo); Drug
Lead sponsor: Allergan; Industry
Eligibility: 18 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010
U.S. locations: 1
States / cities: Newport Beach, California

Conditions: Open-Angle Glaucoma, Ocular Hypertension
Interventions: AL-37807 ophthalmic suspension, 0.1%, Timolol gel forming solution, 0.5%, AL-37807 ophthalmic solution vehicle, Latanoprost ophthalmic solution; Drug · Other
Lead sponsor: Alcon Research; Industry
Eligibility: 18 Years and older
Enrollment: 129 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 1
States / cities: Fort Worth, Texas

Conditions: Glaucoma, Ocular Hypertension
Interventions: Brimonidine 0.2%/Timolol 0.5% Fixed Combination Ophthalmic Solution, Concurrent brimonidine 0.2% and 0.5% timolol; Drug
Lead sponsor: Allergan; Industry
Eligibility: 18 Years and older
Enrollment: 604 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2007
U.S. locations: 1
States / cities: Newport Beach, California

Conditions: Ocular Hypertension, Open Angle Glaucoma
Interventions: BOL-303259-X, Timolol maleate; Drug
Lead sponsor: Bausch & Lomb Incorporated; Industry
Eligibility: 40 Years to 90 Years
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 1
States / cities: La Jolla, California

Conditions: Glaucoma, Ocular Hypertension
Interventions: bimatoprost /timolol formulation A fixed combination ophthalmic solution, bimatoprost/timolol fixed combination ophthalmic solution; Drug
Lead sponsor: Allergan; Industry
Eligibility: 18 Years and older
Enrollment: 561 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 1
States / cities: Artesia, California

Conditions: Glaucoma and Ocular Hypertension
Interventions: DE-117 Ophthalmic Solution, Timolol Maleate Ophthalmic Solution 0.5%; Drug
Lead sponsor: Santen Inc.; Industry
Eligibility: 12 Months and older
Enrollment: 417 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 34
States / cities: Chandler, Arizona • Prescott, Arizona • Glendale, California + 29 more

Conditions: Primary Open-Angle Glaucoma, Ocular Hypertension
Interventions: Bimatoprost, Timolol 0.5%, Placebo Eye Drops, Placebo Ocular Insert; Drug · Device
Lead sponsor: ForSight Vision5, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 169 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 10
States / cities: Artesia, California • La Jolla, California • Newport Beach, California + 7 more

Conditions: Glaucoma, Primary Open Angle, Ocular Hypertension
Interventions: WB007 0.05%, WB007 0.15%, WB007 0.4%, Timolol 0.5%; Drug
Lead sponsor: Bausch & Lomb Incorporated; Industry
Eligibility: 18 Years and older
Enrollment: 77 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 1
States / cities: Newport Beach, California

Conditions: Primary Open Angle Glaucoma, Ocular Hypertension
Interventions: DE-126 Ophthalmic Solution 0.002% QD, Timolol Maleate Ophthalmic Solution 0.5% BID; Drug
Lead sponsor: Santen Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 323 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 41
States / cities: Chandler, Arizona • Phoenix, Arizona • Sun City, Arizona + 34 more

Conditions: Wound Heal
Interventions: Timolol 0.25% Ophthalmic Solution, Standard Wound Care; Drug · Other
Lead sponsor: Keith G. LeBlanc, Jr, MD; Other
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Metairie, Louisiana

Search by objective public record fields.

Trial to Evaluate the Safety and Efficacy of the Second Generation Travoprost Intracameral Implant

An Evaluation of the Fixed Combination Brimonidine Tartrate 0.2%/ Timolol Maleate 0.5% to Latanoprost 0.005% in Glaucoma or Ocular Hypertension Subjects

Travoprost Ophthalmic Topical Cream for Open-angle Glaucoma or Ocular Hypertension

Study of Netarsudil (AR-13324) Ophthalmic Solution in Patients With Glaucoma or Ocular Hypertension

Aqueous Humor Dynamic Components That Determine Intraocular Pressure Variance

Phase 2b Study Evaluating Safety and Efficacy of OTX-TP Compared to Timolol Drops in the Treatment of Subjects With Open Angle Glaucoma or Ocular Hypertension

Evaluation of the Safety and Efficacy of the Bimatoprost Implant System Used in Combination With the SpyGlass IOL Compared to Timolol Ophthalmic Solution (Rhone)

A Study of Glaucoma Therapy to Treat Open-Angle Glaucoma or Ocular Hypertension

A Phase II Study to Evaluate the Additivity of Trabodenoson to Latanoprost in Adults With Ocular Hypertension or Primary Open-Angle Glaucoma

Efficacy of Simbrinza and Rocklatan vs Cosopt and Latanoprost

Adaptive Optics OCT Evaluation of Rhopressa's Effects on the Retinal Ganglion Cells in Glaucoma Patients

Safety and Efficacy Study of Brimonidine/Timolol Fixed Combination in Patients With Glaucoma or Ocular Hypertension

The Secondary Beneficial Effects of Prostaglandin Analog Treatment in Thyroid Eye Disease Patients.

Comparing Safety and Efficacy of Combigan® and Lumigan® With Lumigan® Alone in Glaucoma or Ocular Hypertension Subjects Treated With Xalatan®

Safety and Pharmacodynamics Study of AGN-207281 Ophthalmic Solutions Compared With Timolol Ophthalmic Solution or Placebo in Patients With Ocular Hypertension or Primary Open-Angle Glaucoma

Adjunctive Study of AL-37807 Ophthalmic Suspension

Study to Evaluate Safety of Brimonidine/Timolol Fixed Combination in Glaucoma or Ocular Hypertension Patients

BOL-303259-X With Timolol 0.5% in Subjects With Open-Angle Glaucoma or Ocular Hypertension

Safety and Efficacy of a New Formulation of Bimatoprost/Timolol Ophthalmic Solution Compared With Bimatoprost/Timolol Ophthalmic Solution in Patients With Glaucoma or Ocular Hypertension

A Phase III Study Assessing the Efficacy and Safety of DE-117 Ophthalmic Solution Compared With Timolol Maleate Ophthalmic Solution 0.5% in Subjects With Glaucoma or Ocular Hypertension - Spectrum 4 Study

Bimatoprost Ocular Insert Compared to Topical Timolol Solution in Patients With Glaucoma or Ocular Hypertension

Safety and IOP-Lowering Effects of WB007

Multicenter Study Assessing the Efficacy and Safety of DE-126 Ophthalmic Solution 0.002% Compared With Timolol Maleate Ophthalmic Solution 0.5% in Subjects With Primary Open Angle Glaucoma or Ocular Hypertension

Topical Timolol: a Comparison of Surgical Outcomes